Head-To-Head Comparison: Palisade Bio (NASDAQ:PALI) versus Zoetis (NYSE:ZTS)

Zoetis (NYSE:ZTS) and Palisade Bio (NASDAQ:PALI) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Earnings and Valuation

This table compares Zoetis and Palisade Bio”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.47 billion	3.18	$2.67 billion	$6.07	11.99
Palisade Bio	$250,000.00	1,178.07	-$16.78 million	($0.48)	-3.52

Zoetis has higher revenue and earnings than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Zoetis has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500. Comparatively, Palisade Bio has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500.

Institutional & Insider Ownership

92.8% of Zoetis shares are owned by institutional investors. Comparatively, 11.8% of Palisade Bio shares are owned by institutional investors. 0.2% of Zoetis shares are owned by company insiders. Comparatively, 0.1% of Palisade Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Zoetis and Palisade Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zoetis	27.49%	74.89%	18.59%
Palisade Bio	N/A	-33.47%	-31.79%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Zoetis and Palisade Bio, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	2	9	8	0	2.32
Palisade Bio	1	0	7	2	3.00

Zoetis currently has a consensus target price of $101.08, indicating a potential upside of 38.92%. Palisade Bio has a consensus target price of $9.83, indicating a potential upside of 481.85%. Given Palisade Bio’s stronger consensus rating and higher probable upside, analysts clearly believe Palisade Bio is more favorable than Zoetis.

Summary

Zoetis beats Palisade Bio on 10 of the 15 factors compared between the two stocks.

About Zoetis

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

About Palisade Bio

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.